Vertaling van "information required for healthcare within " (Nederlands → Frans) :

Ook in Europese context wordt de toestemming van de patiënt als “good medical practice” bestempeld, zoals blijkt: “Although consent can be presumed for the recording and sharing of information required for healthcare within the immediate healthcare team, it is good practice to obtain specific consent for this process, particularly in relation to sensitive information.
Le consentement du patient est également considéré dans le contexte européen comme une « good medical practice », ainsi : « Bien que le consentement soit présumé pour l’enregistrement et le partage d’informations requises pour la prestation des soins de santé au sein de l’équipe directe de soins, il est judicieux, dans la pratique, d’obtenir un accord spécifique pour ceci, particulièrement pour ce qui concerne des informations sensibles.

In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information
In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information

Selected projects awaiting regulatory decisions Completed submissions Product Indication US EU Japan News update ABF656 Hepatitis C Q4 2009 - Dossier for ABF656 at once-everytwo-weeks dosing was withdrawn in EU in April since additional information would be requested that could not be generated within required timeframe
Projets importants en attente de décisions réglementaires Demandes déposées Produit Indication USA UE Japon Mise à jour ABF656 Hépatite C T4 2009 - Le dossier d’ABF656 comportant une dose unique toutes les 2 semaines a été retiré de l’UE en avril, car l’information supplémentaire requise ne pouvait pas être fournie dans le délai imparti

The BUM department is legally required to provide support with putting online the list of medicines authorised in Belgium for new medicine MA and of the official information (Summary of Product Characteristics for healthcare professionals and leaflet for the general public).
The BUM department is legally required to provide support with putting online the list of medicines authorised in Belgium for new medicine MA and of the official information (Summary of Product Characteristics for healthcare professionals and leaflet for the general public).